Motif Bio wants to raise £19.4m to further develop iclaprim, its novel antibiotic candidate for acute bacterial skin and skin structure infections.
Motif Bio PLC wants to raise £19.4m ($25m) through issuing new ordinary shares. It will use the money to complete its second Phase III study for iclaprim, its novel antibiotic for acute bacterial skin and skin structure infections (ABSSI) and to file for an NDA and marketing authorization.
Iclaprim, a DHFR (dihydrofolate reductase) inhibitor, is expected to pass through Phase III studies and FDA approval and will likely...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
